Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 605
Summary
- Conditions
- COVID-19
- Sars Cov 2
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: CLARITY is a randomised control trial of two parallel groups; Standard Care + Angiotensin Receptor Blocker (ARB) Standard Care Participants will be randomised in a 1:1 ratio. Randomisation will be stratified according to country and whether the participant is planned for hospital admission or home-based care.Masking: Single (Outcomes Assessor)Masking Description: Trial Statistician and sponsor staff will remain blinded to treatment allocation throughout the trial.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04394117
- Collaborators
- Not Provided
- Investigators
- Study Chair: Meg Jardine National Health and Medical Research Council, Australia
Get Well Soon